Recent news and posts
Assessment of prognostic platforms in the field of breast cancer initiated in Sweden
In the middle of February 2021, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) launched the assessment on prognostic platforms for gene diagnostics in breast cancer used to predict the risk of metastases in patients before using chemotherapy.
The current evaluation is being conducted per request of the Swedish Medical Technologies Product (MTP) Council and includes the following products:
- Oncotype DX;
The assessment is planned to be carried out in the spring of 2021.
See full documents in Swedish here.
This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First, EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).